{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:08:54Z","timestamp":1760123334198,"version":"build-2065373602"},"reference-count":16,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clovis Oncology, GE Healthcare, Lantheus, Janssen, Novartis, Telix Pharmaceuticals, the Prostate Cancer Foundation, and the National Cancer Institute","award":["R01CA235741","R01CA212148","UL1 TR001872"],"award-info":[{"award-number":["R01CA235741","R01CA212148","UL1 TR001872"]}]},{"name":"National Center for Advancing Translational Sciences, National Institutes of Health","award":["R01CA235741","R01CA212148","UL1 TR001872"],"award-info":[{"award-number":["R01CA235741","R01CA212148","UL1 TR001872"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patients with metastatic castration-resistant prostate cancer (mCRPC) who have Prostate-Specific Membrane Antigen (PSMA)-negative disease have inferior outcomes with radioligand therapy (RLT). The objective of this study is to assess the added value of whole-body (WB) diffusion-weighted imaging (DWI) to PSMA PET for identifying PSMA-negative disease, which is important for risk stratification. Methods: Consecutive PSMA PET\/MRI exams at our institution, which included WB DWI in patients with mCRPC, were retrospectively reviewed. For both WB DWI and PSMA PET, two independent readers scored 14 anatomic locations, which were considered positive only if both readers identified lesions. The proportion of patients with mismatched disease was summarized descriptively for each anatomic location and overall. The inter-reader agreement was computed with intra-class correlation coefficients (ICCs). Results: The study included 41 patients (with a mean age of 71.9 years), and WB DWI identified PSMA-negative lesions in 24% of patients. PSMA PET had higher agreement than DWI, although both had good agreement (ICC: 0.87 and 0.72, respectively). The median overall survival was 442 days in those with mismatched disease vs. 523 days in those without, although this difference is not statistically significant (p = 0.49). Conclusions: The addition of WB DWI to PSMA PET can identify PSMA-negative disease, which could alter patient management.<\/jats:p>","DOI":"10.3390\/jcm14061833","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:46:52Z","timestamp":1741585612000},"page":"1833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-6039","authenticated-orcid":false,"given":"Cheng William","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-0543","authenticated-orcid":false,"given":"Spencer C.","family":"Behr","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA"},{"name":"Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-6622","authenticated-orcid":false,"given":"Sina","family":"Houshmand","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA"},{"name":"Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA"},{"name":"Department of Radiology, San Francisco VA Medical Center, San Francisco, CA 94121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"27","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why We Did What We Did: PSMA PET\/CT Selection Criteria for the VISION Trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): A biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Khreish, F., Ribbat, K., Bartholom\u00e4, M., Maus, S., Stemler, T., Hierlmeier, I., Zhang, A.Y., Scott, A.M., Lee, S.-T., and Azad, A.A. (2021). Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT. Cancers, 13.","DOI":"10.3390\/cancers13164134"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","article-title":"Outcome of Patients with PSMA PET\/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis","volume":"63","author":"Hotta","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"pkad077","DOI":"10.1093\/jncics\/pkad077","article-title":"Radium-223 in metastatic castration-resistant prostate cancer: Whole-body diffusion-weighted magnetic resonance imaging scanning to assess response","volume":"7","author":"Parker","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Blackledge, M.D., Tunariu, N., Orton, M.R., Padhani, A.R., Collins, D.J., Leach, M.O., and Koh, D.-M. (2016). Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153840"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/jmri.25196","article-title":"Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop","volume":"44","author":"Taouli","year":"2016","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00330-018-5813-4","article-title":"Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: Diagnostic accuracy and interobserver agreement for nodal and metastatic staging","volume":"29","author":"Johnston","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-017-0327-7","article-title":"Optimal MRI sequences for 68Ga-PSMA-11 PET\/MRI in evaluation of biochemically recurrent prostate cancer","volume":"7","author":"Lake","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-009-1695-9","article-title":"Diagnosis of liver metastases: Value of diffusion-weighted MRI compared with gadolinium-enhanced MRI","volume":"20","author":"Hardie","year":"2010","journal-title":"Eur. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s00330-016-4250-5","article-title":"A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases","volume":"26","author":"Vilgrain","year":"2016","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur. Urol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:30Z","timestamp":1760028570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061833"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061833","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,3,8]]}}}